Published by Alexander Bueso on 27th October 2020
(Sharecast News) - Eli Lilly and researchers at the National Institutes of Health have paused a late-stage clinical trial into a combination of the company's antibody treatment against Covid-19 in combination with Gilead Science's Remdesivir in severely ill patients.